Treatment of insulin-dependent diabetes by hematopoietic stem cell transplantation.
Autoimmunity
Diabetes
Hematopoietic stem cell
Transplantation
Journal
Transplant immunology
ISSN: 1878-5492
Titre abrégé: Transpl Immunol
Pays: Netherlands
ID NLM: 9309923
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
10
04
2022
revised:
24
07
2022
accepted:
30
07
2022
pubmed:
5
8
2022
medline:
30
11
2022
entrez:
4
8
2022
Statut:
ppublish
Résumé
Type 1 diabetes (T1D) is an autoimmune disease resulting from the demolition of β-cells that are responsible for producing insulin in the pancreas. Treatment with insulin (lifelong applying) and islet transplantation (in rare cases and severe diseases), are standards of care for T1D. Pancreas or islet transplantation have some limitations, such as lack of sufficient donors and longtime immune suppression for preventing allograft rejection. Recent studies demonstrate that autologous hematopoietic stem cells (HSC) can regenerate immune tolerance against auto-antigens. Taking advantage of this feature, autologous HSC transplantation (auto-HSCT) is likely the only treatment for T1D that is associated with lasting and complete remission. None of the other evaluated immunotherapies worldwide had the clinical efficacy of auto-HSCT. Therapy with auto-HSCT is insulin-independent rather than reducing insulin needs or delaying loss of insulin production. This review provided the latest findings in auto-HSCT for treatment of T1D.
Identifiants
pubmed: 35926800
pii: S0966-3274(22)00156-3
doi: 10.1016/j.trim.2022.101682
pii:
doi:
Substances chimiques
Insulin
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101682Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflicts of interest.